Hi @wendy55
I followed up with Roche to find out more info and they provided the following (which is similar to what they told you):
Roche
is discontinuing the supply of Xeloda (capecitabine) 500mg tablets.
As
a research and development-focused company, Roche places investment priority in
therapeutic areas of significant unmet medical need. The company is focusing its resources on bringing new and innovative
medicines to patients.
A
number of generic alternatives to Xeloda continue to be available on the
Pharmaceutical Benefits Scheme (PBS).
Xeloda
500mg tablets will be de-listed from the PBS on 1 April 2019.
Patients
should continue to take their medication as prescribed by their healthcare
professional and always consult with their doctor prior to making any changes
to treatment.
They also commented that they have been communicating this information to oncologists for some time so your oncologist should be aware.
I do hope you're able to make the transition to a suitable alternative with minimal issues.